Research Article
Comparison of Biological Properties of Two Medicinal Extracts of the Tehuacan-Cuicatlan Valley
Table 1
The antibacterial activity of the Cyrtocarpa procera and B. morelensis bark.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sm: Streptococcus mutans ATCC 35668; Sm: Streptococcus mutans clinical case; Sa: Staphylococcus aureus clinical case; Sa 25923: Staphylococcus aureus ATCC 25923; Sa mr: Staphylococcus aureus methicillin resistant; Se 35984: Staphylococcus epidermidis ATCC 35984; Se: Staphylococcus epidermidis clinical case; Se 12228: Staphylococcus epidermidis ATCC 12228; Ef: Enterococcus faecalis clinical case; Ef 29212: Enterococcus faecalis ATCC 29212; Av: Actinomyces viscosus clinical case; Pa: Pseudomonas aeruginosa clinical case; Pag: Pantoea agglomerans clinical case; Ecl: Enterobacter cloacae clinical case; Ec1: Escherichia coli clinical case 1; Ec2: Escherichia coli clinical case 2; Vch: Vibrio cholerae clinical case; Vch Tor: Vibrio cholerae (a clinical isolate corresponding to group 01 that produces enterotoxin and has the “Inaba” serotype and “El Tor” biotype). Na: no activity. |